Healthcare Business

Denali Therapeutics announced early Thursday that it would be progressing its Parkinson’s treatment into late-stage studies in collaboration with Biogen.
Novavax shares hit another all-time high on Wednesday after the company announced positive results from its early stage COVID-19 vaccine study.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Pharmacy and health insurer CVS handily beat expected earnings and revenue estimates for the second quarter.
Regeneron Pharmaceuticals, one of the front-runners for the development of a COVID-19 treatment, released an update on its antibody drug combination on Monday.
Alterity Therapeutics stock more than doubled on Tuesday after the company announced new data for its lead drug candidate for the treatment of multiple system atrophy.
Amarin reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its blockbuster drug Vascepa.
All those investors who were buying into the hype that Kodak will be a major player in making materials for generic drugs with a big government loan are being reminded just how chasing news pops in...
CymaBay Therapeutics posted a huge gain to start off the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangitis.
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.
When Merck & Co. (NYSE: MRK) reported its second-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had earnings per share (EPS) of $1.37 and...
Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing,...
Investors have flocked to the dividends of Big Pharma and flocked to the limitless upside of major biotech outfits for years. Valuations are no longer considered high for these two healthcare...
Johnson & Johnson has announced that it will launch its human study for its lead vaccine candidate in the United States and Belgium.
Edesa Biotech joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study. Investors were quick to give this firm the coronavirus bump, more...